Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
Open Access
- 1 November 2014
- journal article
- research article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 8 (6) , 554-561
Abstract
No abstract availableKeywords
Funding Information
- Regeneron Pharmaceuticals
This publication has 31 references indexed in Scilit:
- A systematic review of statin-induced muscle problems in clinical trialsAmerican Heart Journal, 2014
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsJACC, 2014
- An assessment by the Statin Muscle Safety Task Force: 2014 updateJournal of Clinical Lipidology, 2014
- Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient educationJournal of Clinical Lipidology, 2013
- Treatment strategies in patients with statin intolerance: The Cleveland Clinic experienceAmerican Heart Journal, 2013
- Insights Into PCSK9, Low-Density Lipoprotein Receptor, and Low-Density Lipoprotein Cholesterol MetabolismCirculation, 2013
- PCSK9 inhibitorsCurrent Opinion in Lipidology, 2013
- Effect of Statins on Skeletal Muscle FunctionCirculation, 2013
- Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin usersJournal of Clinical Lipidology, 2012
- Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO StudyCardiovascular Drugs and Therapy, 2005